C&C Group plc (CCR)
London Exchange · UK · prices in GBX · close of 22 Oct 2026
Key indicators
| Last close | GBX 101.80 |
|---|---|
| 52-week range | 85.40 – 142.40 |
| Return, 1 month / 3 months | −5.9% / −0.4% |
| Return, 1 year / 3 years | −24.1% / −19.6% |
| Trend | Below its 200-day average |
| RSI (14) | 57 |
| Volatility (1 year) | 35.2% |
| Worst drawdown (1 year) | -34.2% |
| Average daily value traded | 131.58M GBX |
| Dividend yield | 4.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
C&C Group plc is a drinks company based in Dublin, Ireland. It makes and sells cider, including its Bulmers and Magners brands, and also produces Tennent's lager. The company supplies pubs, bars, restaurants and retailers, and runs a distribution business that brings beer, wine and spirits to customers in Ireland and the United Kingdom. Its products are sold in shops and licensed premises, and it also exports cider to markets overseas.
On this site C&C Group plc appears as a stock on the London Exchange (UK), code CCR, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
C&C Group plc (CCR) trades on the London Exchange in UK. It last closed at GBX 101.80 on 22 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 2,305 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 24.1% and over the last three months it fell 0.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 35 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -2.0% | ||
| From 52-week high | -27.8% | ||
| Momentum | 32 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -0.4% | ||
| 6-month return | -14.8% | ||
| 12-month return, skipping the last month | -19.4% | ||
| Stability (higher is calmer) | 45 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 35.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -34.2% | ||
| Liquidity | 90 · Strong | Trades actively. | |
| Average daily value traded | 131.58M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 42 · Weak | Dividend is small or irregular. | |
| Dividend yield | 4.7% | ||
| Years with dividends | 4 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.1% |
|---|---|
| 1 month | −5.9% |
| 3 months | −0.4% |
| 6 months | −14.8% |
| 1 year | −24.1% |
| 3 years | −19.6% |
| 5 years | −51.6% |
Signals
| 50-day / 200-day average | 98.01 / 103.88 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.91 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 Jun 2026 | EUR 0.0367 |
| 13 Nov 2025 | EUR 0.0208 |
| 12 Jun 2025 | EUR 0.0413 |
| 14 Nov 2024 | EUR 0.0200 |
| 18 Jul 2024 | EUR 0.0397 |
| 9 Nov 2023 | EUR 0.0189 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.